- Home
- CGO vs MGNX Comparison
CGO vs MGNX Comparison
Compare CGO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- MGNX
- Stock Information
- Founded
- CGO 2004
- MGNX 2000
- Country
- CGO United States
- MGNX United States
- Employees
- CGO N/A
- MGNX N/A
- Industry
- CGO Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- MGNX Health Care
- Exchange
- CGO Nasdaq
- MGNX Nasdaq
- Market Cap
- CGO 121.2M
- MGNX 99.7M
- IPO Year
- CGO N/A
- MGNX 2013
- Fundamental
- Price
- CGO $12.28
- MGNX $1.76
- Analyst Decision
- CGO
- MGNX Hold
- Analyst Count
- CGO 0
- MGNX 6
- Target Price
- CGO N/A
- MGNX $3.20
- AVG Volume (30 Days)
- CGO 34.7K
- MGNX 617.2K
- Earning Date
- CGO 01-01-0001
- MGNX 11-04-2025
- Dividend Yield
- CGO 9.25%
- MGNX N/A
- EPS Growth
- CGO N/A
- MGNX N/A
- EPS
- CGO N/A
- MGNX N/A
- Revenue
- CGO N/A
- MGNX $165,495,000.00
- Revenue This Year
- CGO N/A
- MGNX N/A
- Revenue Next Year
- CGO N/A
- MGNX N/A
- P/E Ratio
- CGO N/A
- MGNX N/A
- Revenue Growth
- CGO N/A
- MGNX 303.47
- 52 Week Low
- CGO $7.90
- MGNX $0.99
- 52 Week High
- CGO $10.93
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- CGO 64.06
- MGNX 52.37
- Support Level
- CGO $12.21
- MGNX $1.69
- Resistance Level
- CGO $12.20
- MGNX $1.83
- Average True Range (ATR)
- CGO 0.15
- MGNX 0.11
- MACD
- CGO -0.00
- MGNX 0.01
- Stochastic Oscillator
- CGO 85.60
- MGNX 64.00
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.